Key statistics
As of last trade Calidi Biotherapeutics Inc (CLDI:ASQ) traded at 0.7968, 9.98% above its 52-week low of 0.7245, set on Feb 10, 2026.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 0.75 |
|---|---|
| High | 0.84 |
| Low | 0.75 |
| Bid | 0.75 |
| Offer | 0.84 |
| Previous close | 0.76 |
| Average volume | 87.64k |
|---|---|
| Shares outstanding | 7.17m |
| Free float | 5.50m |
| P/E (TTM) | -- |
| Market cap | 5.45m USD |
| EPS (TTM) | -9.62 USD |
Data delayed at least 15 minutes, as of Feb 13 2026 18:21 GMT.
More ▼
Announcements
- Calidi Biotherapeutics To Present on its New Approach to Bispecific T-Cell Engagers (BiTEs) Using its RedTail Platform in a Late-Breaking Abstract at the 2026 AACR-IO Conference
- Calidi Biotherapeutics Provides Corporate Update and Key Value Drivers for 2026
- Calidi Biotherapeutics Announces Exclusive Live Investor Webinar and Q&A Session on November 19, 2025
- Calidi Biotherapeutics Reports Third Quarter 2025 Financial Results and Recent Operational Highlights
- Calidi Biotherapeutics Presents New Data on its Therapeutic Lead, CLD-401, at the 2025 SITC Annual Meeting and Holds Its First Investor Day at SITC
- Calidi Biotherapeutics Announces Investor Event to be Held on Friday, November 7th at the 2025 SITC Annual Meeting
- Calidi Biotherapeutics Announces New Data to be Presented on its Therapeutic Lead, CLD-401, at the 2025 SITC Annual Meeting
- Calidi Biotherapeutics Announces Establishment of Scientific Advisory Board to Support Development of CLD-401 and Advance its RedTail Platform for the Systemic Delivery of Targeted Genetic Medicine
- Calidi Biotherapeutics to Present at the second annual Oncology Venture, Innovation, and Partnering Summit in Boston
- Calidi Biotherapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
More ▼
